Shoulder Implant for Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new shoulder implant for individuals with arthritis and a severely damaged rotator cuff. The goal is to determine the safety and effectiveness of these implants in shoulder surgeries. Researchers are evaluating two different implants: the Comprehensive Mini Humeral Tray and the Comprehensive Reverse Augmented Glenoid, to assess their performance in surgeries. This trial may suit individuals with severe shoulder arthritis and a very weak rotator cuff, particularly if previous shoulder surgeries were unsuccessful. Participants must be able and willing to attend all follow-up appointments. As an unphased trial, this study provides a unique opportunity to contribute to the development of innovative shoulder implants.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this shoulder implant is safe for arthritis patients?
Research has shown that the Comprehensive Mini Humeral Tray used in shoulder treatments yields promising results. Patients report improved shoulder movement and reduced pain. The implant remains stable and well-received, indicating general tolerance.
For the Comprehensive Reverse Augmented Glenoid, studies indicate a good initial track record. It effectively helps restore shoulder function. Short-term safety appears positive, though information on long-term use is limited.
Both treatments seem safe and stable for short-term improvement of shoulder issues. However, the long-term effects of the glenoid remain unclear.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the Comprehensive Mini Humeral Tray and the Comprehensive Reverse Porous Augmented Glenoid because these devices offer new approaches for patients with severe rotator cuff deficiencies. Unlike traditional shoulder implants, which may not fully accommodate the anatomical and functional deficits in these patients, these new devices are designed specifically for reverse shoulder arthroplasty. The Comprehensive Mini Humeral Tray provides a more compact design that fits better with the patient's existing shoulder structure, potentially leading to improved mobility and reduced recovery time. Meanwhile, the Comprehensive Reverse Porous Augmented Glenoid features a porous design that promotes better bone integration, offering greater implant stability and longevity. These innovations could significantly improve outcomes for individuals suffering from arthritic shoulder conditions with rotator cuff deficiencies.
What evidence suggests that this shoulder implant is effective for arthritis?
Research shows that the Comprehensive Mini Humeral Tray, a treatment in this trial used in reverse shoulder replacement surgery, has led to good results. Studies comparing different implant combinations have found stability and effectiveness two years post-surgery. For the Comprehensive Reverse Augmented Glenoid, another treatment option in this trial, special baseplates have improved implant stability and function. These advancements in reverse shoulder replacement have benefited patients with severe shoulder arthritis. Overall, both treatments in this trial have shown promise in enhancing shoulder movement and stability.13678
Who Is on the Research Team?
Hillary Overholser
Principal Investigator
Zimmer Biomet
Are You a Good Fit for This Trial?
This trial is for adults over 18 who need shoulder replacement due to severe arthritis or rotator cuff injuries and have a working deltoid muscle. They must be able to follow the study plan and give informed consent. It's not for those with osteoporosis, metabolic bone diseases, rapid joint destruction, current substance abuse, infection risks, or uncooperative patients.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo reverse shoulder arthroplasty using the Comprehensive Reverse Shoulder System
Follow-up
Participants are monitored for safety and effectiveness after treatment, including implant survivorship and adverse events
What Are the Treatments Tested in This Trial?
Interventions
- Comprehensive Mini Humeral Tray
- Comprehensive Reverse Augmented Glenoid
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zimmer Biomet
Lead Sponsor
Dr. Nitin Goyal
Zimmer Biomet
Chief Medical Officer since 2021
MD from Harvard Medical School
Ivan Tornos
Zimmer Biomet
Chief Executive Officer since 2023
MBA from the University of Miami School of Business, BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business